RLFTF (Relief Therapeutics Holding) Total Stockholders Equity : $55.12 Mil (As of Jun. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Total Stockholders Equity?

Relief Therapeutics Holding's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $55.12 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Relief Therapeutics Holding's Book Value per Share for the quarter that ended in Jun. 2024 was $4.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Relief Therapeutics Holding's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.05.

Relief Therapeutics Holding Total Stockholders Equity Historical Data

The historical data trend for Relief Therapeutics Holding's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Total Stockholders Equity Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

14.55

75.47

197.10

156.09

60.39

Relief Therapeutics Holding Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															166.38	156.09	104.81	60.39	55.12

Relief Therapeutics Holding (OTCPK:RLFTF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Relief Therapeutics Holding's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(55.121	-	0)	/	12.5404
	=	4.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Relief Therapeutics Holding's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.445	+	2.259)	/	55.121
	=	0.05

Relief Therapeutics Holding Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK 0QKQ:UK RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.